Sirt1 acts in association with PPARα to protect the heart from hypertrophy, metabolic dysregulation, and inflammation

Cardiovascular Research

Volumn 90, Issue 2, 2011, Pages 276-284

  Planavila, Ana ^a,b   Iglesias, Roser ^a,b   Giralt, Marta ^a,b   Villarroya, Francesc ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Cardiac hypertrophy; Inflammation; Metabolism; PPAR ; Sirt1

Indexed keywords

FATTY ACID; ISOPRENALINE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHENYLEPHRINE; RESVERATROL; SIRTUIN 1; SYNAPTOTAGMIN I;

ANIMAL CELL; ARTICLE; CELL SIZE; CONTROLLED STUDY; DEACETYLATION; DOWN REGULATION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENE OVEREXPRESSION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART PROTECTION; IMMUNOPRECIPITATION; INFLAMMATION; METABOLIC DISORDER; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; WILD TYPE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOMEGALY; CARDIOTONIC AGENTS; CELLS, CULTURED; ENERGY METABOLISM; FATTY ACIDS; GENE EXPRESSION; LIPID METABOLISM; MICE; MICE, MUTANT STRAINS; MYOCARDITIS; MYOCYTES, CARDIAC; NF-KAPPA B; OXIDATION-REDUCTION; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; SIRTUIN 1; STILBENES;

EID: 79955397959     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq376     Document Type: Article

References (34)

1. van Bilsen M, van der Vusse GJ, Reneman RS. Transcriptional regulation of metabolic processes: implications for cardiac metabolism. Pflugers Arch 1998;437:2-14. (Pubitemid 29071305)
2. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 2006;444: 868-874. (Pubitemid 46024994)
3. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127:1109-1122. (Pubitemid 44894520)
4. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De OR et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004;429:771-776. (Pubitemid 38833129)
5. Vinciguerra M, Fulco M, Ladurner A, Sartorelli V, Rosenthal N. SirT1 in muscle physi-ology and disease: lessons from mouse models. Dis Model Mech 2010;3:298-303.
6. Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC et al. Peroxi-some proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 2005;65:832-841. (Pubitemid 40249728)
7. Liang F, Wang F, Zhang S, Gardner DG. Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrin-ology 2003;144:4187-4194. (Pubitemid 37088775)
8. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009;9:327-338.
9. de Vries JE, Vork MM, Roemen TH, de Jong YF, Cleutjens JP, van der Vusse GJ et al. Saturated but not mono-unsaturated fatty acids induce apoptotic cell death in neo-natal rat ventricular myocytes.J Lipid Res 1997;38:1384-1394. (Pubitemid 27332565)
10. Amat R, Planavila A, Chen SL, Iglesias R, Giralt M, Villarroya F. SIRT1 controls the transcription of the peroxisome proliferator-activated receptor-gamma co-activator-1alpha (PGC-1alpha) gene in skeletal muscle through the PGC-1alpha autoregulatory loop and interaction with MyoD. J Biol Chem 2009;284:21872-21880.
11. Planavila A, Laguna JC, Vazquez-Carrera M. Nuclearfactor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J Biol Chem 2005; 280:17464-17471. (Pubitemid 41389218)
12. Smeets PJ, Teunissen BE, Planavila A, de Vogel-van den Bosch H., Willemsen PH, van der Vusse GJ et al. Inflammatory pathways are activated during cardiomyocyte hyper-trophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta. J Biol Chem 2008;283:29109-29118.
13. Lee JH, Song MY, Song EK, Kim EK, Moon WS, Han MK et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 2009;58:344-351.
14. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA et al. Modulation of NF-kappaB-dependenttranscription and cell survival bythe SIRT1 deacetylase. EMBO J 2004;23:2369-2380. (Pubitemid 38954844)
15. Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, Babendure JL et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 2009;29:1363-1374.
16. Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 2002;160:91-102. (Pubitemid 34076646)
17. Delerive P, De BK, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ et al. Peroxi-some proliferator-activated receptor alpha negatively regulates the vascular inflamma-tory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999;274:32048-32054.
18. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005; 434:113-118. (Pubitemid 40349395)
19. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007;100:1512-1521. (Pubitemid 46834764)
20. Alcendor RR, Kirshenbaum LA, Imai S, Vatner SF, Sadoshima J. Silent information reg-ulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res 2004;95:971-980. (Pubitemid 39532327)
21. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010;285:8340-8351.
22. Biala A, Tauriainen E, Siltanen A, Shi J, Merasto S, Louhelainen M et al. Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes. Blood Press 2010; 19:196-205.
23. Thandapilly SJ, Wojciechowski P, Behbahani J, Louis XL, Yu L, Juric D et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dys-function in the SHR without lowering blood pressure. Am J Hypertens 2010;23: 192-196.
24. Wojciechowski P, Juric D, Louis XL, Thandapilly SJ, Yu L, Taylor C et al. Resveratrol arrests and regresses the development of pressure overload-but not volume overload-induced cardiac hypertrophy in rats. J Nutr 2010;140:962-968.
25. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001;107:813-822. (Pubitemid 32274034)
26. Binas B, Danneberg H, McWhir J, Mullins L, Clark AJ. Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization. FASEBJ 1999;13:805-812. (Pubitemid 29220693)
27. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension 1988;11:416-426.
28. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241. (Pubitemid 20225044)
29. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyo-cytes. Proc Natl Acad Sci USA 2001;98:6668-6673. (Pubitemid 32538274)
30. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002;105:509-515. (Pubitemid 34141710)
31. Higuchi Y, Otsu K, Nishida K, Hirotani S, Nakayama H, Yamaguchi O et al. Involve-ment of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol 2002;34:233-240. (Pubitemid 35222832)
32. Gupta S, Purcell NH, Lin A, Sen S. Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol 2002;159:1019-1028. (Pubitemid 36055756)
33. Li Y, Ha T, Gao X, Kelley J, Williams DL, Browder IW et al. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 2004;287:H1712-H1720. (Pubitemid 39313278)
34. Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R et al. Meta-bolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 2007;26:1913-1923. (Pubitemid 46624046)